ABBV Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 3/6 |
AbbVie Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$160.10 |
52 Week High | US$168.80 |
52 Week Low | US$160.10 |
Beta | 0.59 |
1 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -5.15% |
Recent News & Updates
Recent updates
Shareholder Returns
ABBV | PE Biotechs | PE Market | |
---|---|---|---|
7D | 0% | 0% | 0% |
1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how ABBV performed against the PE Biotechs industry.
Return vs Market: Insufficient data to determine how ABBV performed against the PE Market.
Price Volatility
ABBV volatility | |
---|---|
ABBV Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in PE Market | 0% |
10% least volatile stocks in PE Market | 0% |
Stable Share Price: ABBV has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ABBV's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 50,000 | Rick Gonzalez | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
ABBV fundamental statistics | |
---|---|
Market cap | US$290.22b |
Earnings (TTM) | US$5.95b |
Revenue (TTM) | US$54.40b |
49.4x
P/E Ratio5.4x
P/S RatioIs ABBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ABBV income statement (TTM) | |
---|---|
Revenue | US$54.40b |
Cost of Revenue | US$16.77b |
Gross Profit | US$37.63b |
Other Expenses | US$31.68b |
Earnings | US$5.95b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 3.37 |
Gross Margin | 69.17% |
Net Profit Margin | 10.94% |
Debt/Equity Ratio | 924.1% |
How did ABBV perform over the long term?
See historical performance and comparison